Q2-2019 Outsourced Pharma Services Update
The contract development and manufacturing sector observed robust acquisition activity during the second quarter of 2019. Buoyed by increased investment and confidence in gene therapy and biologic drug development, CDMO’s are using transactions to penetrate these markets. Within the CRO space, clinical trial management providers have become an attractive ancillary service line to companies seeking differentiation in an increasing competitive environment.
To print and download the full report, please click below…
Sources: SEC Filings; Company Press Releases, and Reports; IBISWorld; Capital IQ; PHP Estimates and Research. This document has been compiled with publicly available information. Provident Healthcare Partners, LLC makes no guarantee of its accuracy or completeness. No data or statement should be construed to be a recommendation for the purchase, sale, or retention of any security.
